Novavax Advances Development of Novel COVID-19 Vaccine
- Vaccine candidate derived from coronavirus spike (S) protein
- Matrix-M™ adjuvant expected to boost immune responses
- Phase 1 clinical trial planned for late spring
“Our previous experience working with other coronaviruses, including both MERS and SARS, allowed us to mobilize quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates,” said
About Coronaviruses
A new strain of coronavirus first appeared in late 2019 in
About Matrix-M™
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune responses.
About
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
Statements herein relating to the future of
Contacts:
Investors
ir@novavax.com
240-268-2022
Westwicke
john.woolford@westwicke.com
443-213-0506
Media
Brandzone/KOGS Communication
kaplan@kogspr.com
617-974-8659
Source: Novavax, Inc.